Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives $8.50 Consensus Target Price from Analysts

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) has earned an average recommendation of “Moderate Buy” from the eight ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $8.80.

Several equities research analysts have recently issued reports on AUTL shares. Mizuho decreased their target price on Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Tuesday. HC Wainwright started coverage on shares of Autolus Therapeutics in a report on Tuesday, February 17th. They issued a “buy” rating and a $9.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Friday, March 27th. Zacks Research upgraded shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, March 13th. Finally, Truist Financial raised shares of Autolus Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th.

Institutional Investors Weigh In On Autolus Therapeutics

A number of hedge funds have recently modified their holdings of AUTL. Marex Group plc bought a new position in Autolus Therapeutics during the second quarter valued at $28,000. Independent Advisor Alliance purchased a new stake in Autolus Therapeutics in the fourth quarter worth $28,000. SmartHarvest Portfolios LLC bought a new stake in shares of Autolus Therapeutics in the fourth quarter valued at $43,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Autolus Therapeutics during the 3rd quarter valued at $46,000. Finally, R Squared Ltd grew its stake in shares of Autolus Therapeutics by 40.1% during the 3rd quarter. R Squared Ltd now owns 30,476 shares of the company’s stock worth $50,000 after acquiring an additional 8,730 shares during the period. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Stock Up 8.7%

Shares of NASDAQ AUTL opened at $1.38 on Friday. The company has a market capitalization of $367.27 million, a PE ratio of -1.28 and a beta of 1.95. The stock’s 50 day moving average price is $1.48 and its 200-day moving average price is $1.52. Autolus Therapeutics has a twelve month low of $1.11 and a twelve month high of $2.70.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Friday, March 27th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.07). The business had revenue of $24.29 million for the quarter, compared to analysts’ expectations of $23.92 million. Autolus Therapeutics had a negative net margin of 381.40% and a negative return on equity of 99.05%. As a group, research analysts expect that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.